Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay.
Gynecol. Oncol., Nov (2012)
Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Ann. Surg. Oncol., Dec;19(13):4059-67 (2012)
Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer.
Gynecol. Oncol., Sep;126(3):381-6 (2012)
Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes.
Gynecol. Oncol., Aug;126(2):220-3 (2012)
A model for prediction of parametrial involvement and feasibility of less radical resection of parametrium in patients with FIGO stage IB1 cervical cancer.
Gynecol. Oncol., Jul;126(1):82-6 (2012)
Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease.
Gynecol. Oncol., May;125(2):483-92 (2012)
Surgical management of epithelial ovarian cancer.
Clin Obstet Gynecol., Mar;55(1):75-95 (2012)
Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review.
Gynecol. Oncol., May;125(2):477-82 (2012)
Stage I noninvasive and minimally invasive uterine serous carcinoma: comprehensive staging associated with improved survival.
Int. J. Gynecol. Cancer., Feb;22(2):273-9 (2012)
CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study.
Gynecol. Oncol., Feb;124(2):216-20 (2012)
"Kegel ball" induced vaginal cuff dehiscence following radical abdominal hysterectomy: laparoscopically-assisted transvaginal retrieval.
Gynecol. Oncol., Jan;124(1):170 (2012)
Is the easier way ever the better way?
J. Clin. Oncol., Nov;29(31):4073-5 (2011)
Recurrence patterns and surveillance for patients with early stage endometrial cancer.
Gynecol. Oncol., Nov;123(2):205-7 (2011)
Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations.
Am. J. Obstet. Gynecol., Jun;204(6):466-78 (2011)
Feasibility of intravenous gemcitabine and an intraperitoneal platinum agent in the treatment of ovarian cancer.
J Chemother., Jun;23(3):163-7 (2011)
Comparison of candidate serologic markers for type I and type II ovarian cancer.
Gynecol. Oncol., Sep;122(3):560-6 (2011)
Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center.
Gynecol. Oncol., Aug;122(2):319-23 (2011)
Impact of payer status on treatment of cervical cancer at a tertiary referral center.
Gynecol. Oncol., Aug;122(2):324-7 (2011)
A retrospective review of the effect of surgeon specialty on the management of 190 benign and malignant pediatric and adolescent adnexal masses.
J Pediatr Adolesc Gynecol., Oct;24(5):282-5 (2011)
Impact of surgeon and hospital volume on short-term outcomes and cost of oropharyngeal cancer surgical care.
Laryngoscope., Apr;121(4):746-52 (2011)